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In this report, non-stochastic and stochastic 2D atom-based linear indices were used to the discrimination of 
paramphistomicide compounds from inactive ones. Two linear classification-based QSAR models were obtained. 
These equations, performed considering both non-stochastic and stochastic TOMOCOMD-CARDD descriptors, 
classify correctly 88.57% of chemicals in database, for a good Mathew’s correlation coefficient of 0.77. A few 
anthelmintics compounds and other drugs from the Merck Index, Negwer handbook, and Goodman & Gilman 
were selected/identified by the models as possible paramphistomicide, one of them was found in the recent literature 
as possessing this activity. The results demonstrate the usefulness of TOMOCOMD-CARDD method for drug 
discovery of new lead paramphistomicide compounds.
KEYworDS: linear discriminant analysis, TOMOCOMD-CARDD method, atom-based linear indices, QSAR, 
virtual screening, paramphistomicides. 
rESUMEN
En este informe se emplearon índices lineales estocásticos y no estocásticos en 2D, basados en átomos, para discriminar 
los compuestos de acción paramfistomicida de los inactivos. Se obtuvieron dos modelos lineales QSAR basados en 
la clasificación. Estas ecuaciones, llevadas a cabo teniendo en cuenta descriptores TOMOCOMD-CARDD tanto 
estocásticos como no estocásticos, clasifican correctamente el 88,57% de los elementos químicos de la base de datos, 
arrojando un buen coeficiente de correlación de Mathews del 0,77. Los modelos seleccionaron/identificaron algunos 
compuestos antihelmínticos y otros fármacos del índice Merck, del manual Negwer y de Goodman & Gilman 
como posibles paramfistomicidas, y la literatura reciente incluye a uno de ellos como poseedor de esta actividad. Los 
resultados demuestran la utilidad del método TOMOCOMD-CARDD para el descubrimiento de fármacos y de 
nuevos compuestos líderes de acción paramfistomicida.
PALABrAS cLAVE: análisis discriminante lineal, método TOMOCOMD-CARDD, índices lineales basados en átomos, 
QSAR, cribado virtual, paramfistomicidas.
   
INTroDUcTIoN
“Models are to be used, not believed”.
Menger, F.M J.Am.Chem.Soc. 107 (1985) 3105
Paramphistomiasis is one of the important groups of parasitic 
diseases in several continents.1-4 This illness caused by a number of 
species of paramphistomes is responsible for sporadic epizootics of 
acute parasitic enteritis accompanied with persistent fetid diarrhea in 
ruminants.4 Adult flukes in the rumen (first stomach or paunch) or 
reticulum (second stomach or honeycomb) for instance, are not known 
to cause clinical disease. However, heavy infections with immature 
flukes in the upper small intestine can cause serious ill-health and 
death. To control paramphistomiasis, regular use of anthelmintics 
is still the most practicable method.5 Chemotherapeutic trials have 
been conducted under both natural and experimental conditions with 
variable results. 
There is a danger of being swept up in the hype and excitement 
surrounding the area of bioinformatic and it is clear that in silico 
predictive modeling does not represent a panacea for the industry. 
However, nowadays is accepted that the implementation and 
integration of the opportunity presented by in silico modeling needs 
to be carried out in a “rational” and systematic manner.6 The creation 
of new lead-paramphistomicide compounds by this experimental 
approach (probe and error method) is a long and complicated process 
which is based on several factors.6 An alternative to the “real” world 
of synthesis and screening of compounds in the laboratory is an in 
silico “virtual” world of data, analysis, hypothesis and design that 
reside inside a computer. By this means, “the expensive commitment 
to actual synthesis and bioassay is made only after exploring the initial 
concepts with computational models and screens”.7 
Predictive in silico models could be used for structural subsystems 
identification (from large databases or libraries), accelerating the 
selection/identification of lead-paramphistomicide compounds.6 
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Therefore, predictive modeling has the potential to transform early-
stage drug discovery. In connection, computer-aided drug design has 
emerged as a rational alternative in the search for novel drugs.7-8 and 
medicinal chemists are called to developing more efficient strategies 
for the search of novel candidates to be assayed as paramphistomicide 
drugs. In relation with it, TOMOCOMD-CARDD (acronym of 
the TOpological MOlecular COMputer Design-Computed-Aided 
Rational Drug. 
Design) method has demonstrated to be a useful approach for 
discovery (identification/selection) of new lead or drug-like compounds 
with desirable activities.9-20
The main aims of this paper follow: 1) to develop quantitative 
models that discriminates paramphistomicide compounds from the 
inactive ones using TOMOCOMD-CARDD approach (2D atom-
based linear indices) and Linear Discriminant Analysis (LDA), and 2) 
to perform a virtual (computational) screening for the search of new 
lead-paramphistomicide compounds.
In order to assure an adequate extrapolation power for the LDA 
models, a data set with a great molecular diversity was chosen. We 
have selected 35 organic chemicals for making up the data set, 20 with 
paramphistomicide activity, considering different modes of action, and 
the rest, 15, without this parasiticide activity (inactives).21-70 Table SD1 
gives the names of all the drugs studied (see supplementary data). 
It is remarkable to stand out that, the most critical aspect of the 
construction of the training (learning) sets is to warranty a great 
molecular and action modes diversity in this data set. Figure 1 depicts 
a representative sample of such drugs. Both active and inactive 
compounds are representatives of most of the different structural 
patterns and modes of action of anthelmintic drugs, such as: a) agonist 
at nicotinic acetylcholine receptors (levamisole and metyridine); b) 
cholinesterase antagonists (profenofos and trichlorfan); c) glutamate-
gated chloride receptor potentiators (moxidectin); d) increased 
calcium permeability (praziquantel); e) Inhibition of microtubule 
formation (albendazole, netobimin and fenbendazole); f ) proton 
ionophores (bithionol, niclosamide, and rafoxanide); g) inhibition of 
phosphoglycerate kinase and mutase (clorsulon), and so on.71-72
Later, the molecular structure of each organic-chemical compounds 
in dataset was coded using non-stochastic and stochastic 2D atom-
based linear indices.10-12,14,20 These MDs were calculated using the ‘in 
house’ TOMOCOMD-CARDD software.9 The total and local (atom, 
group, and atom-type) linear indices for small-to-medium sized organic 
compounds have been explained in some detail in the literature.10-
12,14,20 The atom-based TOMOCOMD-CARDD MDs computed 
in this study were the following: i) kth (k = 15) total (global) non-
stochastic atom-based linear indices not considering and considering 
H-atoms in the molecule [fk( x ) and fkH( x ), respectively], ii) kth (k 
= 15) local (group = heteroatoms: S, N, O) atom-based linear indices 
not considering and considering H atoms in the molecule, fkL( x E) 
and fkL
H( x E), correspondingly. These local descriptors are putative 
molecular charge, dipole moment, and H-bonding acceptors, iii) kth 
(k = 15) local (atom-type = H atoms bonding to heteroatoms: S, N, 
O) atom-based linear indices considering H atoms in the molecule, 
fkL
H( x E-H),. These local descriptors are putative H-bonding donors 
(hydrogen bonding capacity), lipophilicity, and so on, and iv) The kth 
total [sfk( x ) and sfkH( x )] and group [sfk( x E), sfkH( x E) and sfkH( x
E-H)] atom-based stochastic linear indices were also computed. Here, we 
used the symbols fk( x ) and sfk( x ) for non-stochastic and stochastic 
atom-based linear indices, respectively.10-12,14,20 
LDA, an heuristic algorithm capable of distinguishing among 
two or more categories of objects, is a useful technique to find 
discriminant functions with the ability to distinguish between two 
groups or populations.73 To derive discriminant functions that permit 
the classification of lead-like compounds as positive (presence of 
paramphistomicide activity) or negative (absence of paramphistomicide 
activity), we used LDA in which non-stochastic and stochastic 
atom-based linear indices were used as independent variables. For 
obtaining LDA-based QSAR models, we used the statistic package 
STATISTICA.74 Forward stepwise procedure was fixed as the strategy 
for variable selection and the principle of parsimony (Occam’s razor) 
was taken into account as strategy for model selection.75 The quality 
of the models was mainly determined by examining Wilk’s lambda (λ) 
parameter (U-statistic) and the Mahalanobis distance (D2). We also 
inspected the Fisher ratio (F), the p level (p), and the ratios between the 
cases and the variables in the equation and variables to be explored in 
order to avoid overfitting or chance correlation as well as the percentage 
of good classification in the training and test sets.74,75 Validation of 
the models was also corroborated by means of a leave-one-out (LOO) 
cross-validation procedure. We also developed the linear discriminant 
canonical analysis by checking the following statistic: Canonical 
regression coefficient (Rcan), Chi-squared and its p-level [p(χ
2)].76
Discriminant ability was assessed in terms of the proportion of 
correct classifications in each set. The classification of cases was 
performed by means of the posterior classification probabilities. By 
using the models one compound can be then classified as active, if 
∆P% > 0, being ∆P% = [P(Active) - P(Inactive)]x100 or as inactive 
otherwise. P(Active) and P(Inactive) are the probabilities that the 
equations classify a compound as active and inactive, respectively. 
The probability that a case belongs to a particular group is basically 
proportional to the Mahalanobis distance from that group centroid. 
In closing, the posterior probability is the probability, based on our 
knowledge of the values of others variables, that the respective case 
belongs to a particular group. 
The classification obtained models are given below together with the 
LDA-statistical parameters:
Class = 3.34 +2.76x10-2f3( x ) -7.57x10-9f15( x ) -4.01f1( x ) -
                7.16x10-5f11L( x Hal)  +1.99x10-6f14L( x Hal)                                                                           
                (1)
N = 35        λ = 0.445        F(5.29) = 7.1266        Rcan = 0.74        
x2 = 24.44  
  
Mean (+) = -0.93        Mean (-) = 1.24        C =  0.77      
 Q = 88.57%        p<0.0002
Class =  3.79 +1.39 f0
H( x ) -2.98 f2H( x ) +10.28 f11H( x ) 
                +1.14 f14
H( x )   -9.87 f15H( x )                                                                                                
(2)                                 
N = 35        λ = 0.49        F(5.29) = 5.9642        Rcan = 0.71       
x2 = 21.57    
Mean (+) =  0.85       Mean (-) = -1.13        C =  0.77      
 Q = 88.57%        p<0.0007
where N is the number of compounds. The classification results 
(including the canonical scores) for the database (active and inactive 
ones) with the models 1 and 2 is given as Table 1. In addition, we 
provide a plot with the ∆P% for the actives and inactives using the 
non-stochastic and stochastic atom-based linear indices (see Figures 
2 and 3). 
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In Table 2 we illustrate the results obtained in the classification of 
compounds of the data set using both MDs. As it can be observed 
in Table 2 both fitted models exhibit good results. These two models 
correctly classified the 88.57% (accuracy) of the training set and 
showed high Matthews correlation coefficients (C) of 0.77. Table 2 
also depicts the values of specificity, sensitivity and false positive rate 
(also known as ‘false alarm rate’), statistical parameters very used in 
QSAR studies.77
To assess the predictability of the discriminant models, a LOO cross-
validation was carried out. This methodology systematically removed 
one data point at a time from the data set. A discriminant model was 
then constructed on the basis of this reduced data set and subsequently 
used to predict the removed data point. This procedure was repeated 
until a complete set of predicted classification was obtained. The global 
classification of the LOO cross-validation procedure was the same that 
for data set in both equations (accuracy of 88.57%). 
On the other hand, the massive cost of developing new drugs, coupled 
with candidate attrition rates during the discovery and development 
processes, highlights the need for a ‘sea change’ in the drug discovery 
paradigm.6 In order to reduce costs, pharmaceutical companies have 
to find new technologies to replace the old ‘hand-crafted’ synthesis 
and testing new chemical entities (NCE) approaches.78 In this sense, 
cheminformatics can be used to analyze data from high-throughput 
screening (HTS) and other forms of chemistry, thereby aiding in the 
identification of optimal lead structures.79 In this sense, ligand-based in 
silico screening80 has emerged as an interesting alternative to HTS.81,82 
By this means, computational techniques are used to select a reduced 
number of potentially active compounds from large available chemical 
or virtual combinatorial libraries. The main aim of this approach is to 
discriminate potent candidate molecules from inactive ones. This kind 
of in silico studies avoid the expensive commitment to actual synthesis 































































































































Figure 1. Random, but not exhaustive, sample of the molecular families of compounds studied here.
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Table 1. Name, Posterior Probabilities (∆P%) and Canonical Scores of Chemicals in
Data Set by Obtained Models.





Cupper Sulphate 97,98 -2,14 79,78 0,96
Tetrachloromethane 91,22 -1,45 83,31 1,07
Hexachloroethane 4,92 -0,08 85,08 1,13
Hexachlorophene 99,56 -2,84 95,26 1,73
Bethionol 75,16 -0,93 86,04 1,16
Trichlorfan 93,84 -1,62 93,00 1,52
**Niclosamide 86,12 -1,22 -1,73 -0,16
Oxyclozanide 90,27 -1,40 90,86 1,39
Niclofolan 69,94 -0,83 45,93 0,36
Brotianide 53,73 -0,58 96,50 1,88
*CGA (2-tertiary-butylbenzthiazole) -66,54 0,71 86,30 1,17
Resorantel 50,03 -0,54 15,00 0,01
*Triclabendazole -4,77 0,01 73,28 0,80
Levamisol 88,53 -1,32 9,61 -0,05
Thiobisdichloropheno 79,22 -1,02 86,71 1,19
Febantel 29,93 -0,31 96,91 1,95
Bethionol sulphoxide 98,17 -2,19 87,50 1,22
**Metyridine 37,86 -0,40 -33,35 -0,49
Fenbendazole 29,95 -0,32 4,19 -0,10
Dichlorophen 16,76 -0,19 44,53 0,34
Inactive Group
Hexachloroparaxilol -80,73 1,00 -71,42 -1,04
*Phenotiazine 52,08 -0,56 -9,86 -0,24
Hetolin -99,86 3,33 -99,59 -3,25
Closantel -85,03 1,13 -60,89 -0,85
Moxidectin -99,13 2,47 -98,31 -2,55
**Clorsulon -99,89 3,43 63,55 0,61
Albendazole -82,48 1,05 -81,04 -1,28
Profenofos -97,38 1,96 -95,98 -2,10
Netobimin -87,68 1,22 -99,20 -2,92
Mebendazole -91,23 1,39 -3,12 -0,17
Rafoxanide -77,95 0,93 -23,52 -0,38
Oxfendazole -84,52 1,11 -2,03 -0,16
Mintic -0,25 -0,03 -59,62 -0,83
***Nitroxynil 11,80 -0,14 71,30 0,76
Praziquantel -41,91 0,38 -98,64 -2,65
aIncorrect classifications from Eqs. 1 or 2 are marked with (*) or (**), respectively. b∆P% = [P(+) - P(-)]*100, where P(+) is the posterior 
probability with which the chemical is predicted as paramphistomicide and P(-) is the posterior probability with which the chemical is 
predicted as inactive. cCanonical scores obtained using canonical analysis.
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Here we develop a virtual search of paramphistomicide 
compounds by using the discriminant functions obtained through 
the TOMOCOMD-CARDD method. Firstly, we select compounds 
to which had been reported anthelmintic activity,83-85 but not have 
been assay as paramphistomicide. Table SD2 (see supplementary 
data) depicts the result of the TOMOCOMD-CARDD classification 
of anthelmintics in an external set. A few anthelmintics were selected 
by the discriminant function as possible paramphistomicides. We also 
looked for these compounds in the literature in order to determine if 
they have been reported as possessing the paramphistomicide activity. 
In connection, diamphenethide was identified as inactive by obtained 
models and this molecule has been reported in the literature as 
ineffective (at 10-1M) in vitro test.29 In the same in vitro experiment, the 
sodium arsenite show high paramphistomicide activity and this organic 
chemical was identified successful by developed TOMOCOMD-
CARDD’s models. This result is the most important validation for 
these QSAR equations, because it has been able to detect a series of 
anthelmintics as paramphistomicide from a database and some of these 
compounds have shown the predicted activity at in vitro assays.29
Finally, we had performed an exhaustive search in the Merck Index,83 
Negwer handbook,84 and Goodman & Gilman85 looking for organic-
chemical compounds to be evaluated in the models. These chemicals are 
drugs or drugs-like compounds, which have well-established methods 
of synthesis and in many cases their toxicological, pharmacodynamical 
and pharmaceutical properties are well-known. A few compounds were 
identified by the classification function as possible paramphistomicides, 
among them we can find known drugs with other pharmacological 
properties (for more detail see Table SD3 at supplementary data). There 
is great variability in the functions of these chemicals and also there is 
great variability in their molecular structures. Nevertheless, most of 
these compounds identified as actives but not reported in the literature 
as anthelmintic or paramphistomicides are now in experimental test in 
order to demonstrate their pharmacological activity. 
In conclusion, in this study two models was obtained and successfully 
applied to the search for drugs-like compounds, exhibiting significant 
paramphistomicide activity in addition to other pharmacological 
properties. We therefore conclude that simple, straightforward in silico 
tests such as these described here afford useful means for the initial 
selection of new chemicals for further more detailed evaluation as 
possible leads to the development of new and specific veterinary anti-
paramphistomun drugs.















Figure 2. Plot of the ∆P% from Eq. 1 (using non-stochastic 
atom-based linear indices) for each compound in the database. 
Compounds 1-20 are active (paramphistomicides) and chemicals 
21-35 are inactive (non-paramphistomicides).
















Figure 3. Plot of the ∆P% from Eq. 2 (using stochastic atom-based 
linear indices) for each compound in the database. Compounds 1-20 
are active (paramphistomicides) and chemicals 21-35 are inactive 
(non-paramphistomicides).
Table 2. Classification (confusion) matrices and prediction performances for LDA-based QSAR models.
% Correct (-) (+) % Correct (-) (+)
Non-Stocastic (Eq. 1) Stocastic (Eq. 2)
Inactive Group (-) 86.66 13 2 86.66 13 2
Active Group  (+) 90.00 2 18 90.00 2 18











Non-Stocastic (Eq. 1) 0.77 88.57 86.67 86.67 10.00
Stocastic (Eq. 2) 0.77 88.57 86.67 86.67 10.00
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